Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Abciximab (Reopro) and Reteplase When Administered Prior to Catheterization After a Myocardial Infarction

Study:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Reteplase and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Rationale:

n/a

Purpose:

A study of abciximab given with reteplease versus abciximab alone in patient with an acute MI.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Myocardial Infarction
Percutaneous Coronary Intervention
Drug: Abciximab
Drug: reteplase
Drug: abciximab placebo
Drug: abciximab
Drug: reteplase placebo
Phase 3

Verified by Centocor, Inc. December, 2007

Sponsored by: Centocor, Inc.
Information provided by: Centocor, Inc.
ClinicalTrials.gov identifier: NCT00046228

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic Cardiovascular Coordinating Center
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site